• Willingness to sign a written informed consent document .

• Female, age ≥18 yrs and ≤70 yrs.

• Histological or cytological confirmation of epithelial ovarian cancer, carcinoma tube, or primary peritoneal carcinoma.

• Patients with platinum refractory or platinum resistant ovarian cancer:

‣ Platinum refractory: progression during the first platinum-based treatment or within 4 weeks after the first platinum-based primary therapy;

⁃ Platinum resistant: progression during the platinum-based treatment except for platinum refractory, or within 6 months after the last receipt of platinum-based treatment (patients have received platinum containing chemotherapy at least 4 weeks);

⁃ Radiological progression during the last treatment administered;

⁃ no more than 1 prior treatment regimens for recurrent disease.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

• At least 1 lesion can be accurately measured, as defined by RECIST1.1.

• Laboratory criteria are as follows:

‣ Complete blood count: hemoglobin (Hb) ≥90g/L ; absolute neutrophil count (ANC) ≥1.5×109/L ; platelets ≥90×109/L;

⁃ Biochemistry test: serum creatinine(cr) \<1.5×ULN; total bilirubin\<1.5×ULN; alanine aminotransferase(ALT) ,aspartate aminotransferase(AST)≤2.5×ULN; (ALT,AST≦5×ULN if liver involved) ;

⁃ Coagulation test: International Normalized Ratio (INR) \< 1.5, activeated partial thromboplasting time (APTT) \<1.5×ULN

• Life expectancy of at least 3 months.